



## **TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference**

June 2, 2022

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in the JMP Securities Life Sciences Conference on June 16<sup>th</sup>, 2022.

TELA Bio's management is scheduled to present at the JMP Securities Life Sciences Conference on Thursday, June 16<sup>th</sup>, 2022, at 09:030am ET. Interested parties can access the live and archived webcast at [ir.telabio.com](https://ir.telabio.com).

### **About TELA Bio, Inc.**

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit [www.telabio.com](https://www.telabio.com).

### **Investor Contact**

Greg Chodaczek  
332-895-3230  
[ir@telabio.com](mailto:ir@telabio.com)